The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -6,703,557 | -40,703,817 | 28,991,185 | -11,790,697 |
| Depreciation and amortization | 207,371 | 230,824 | 248,253 | 504,629 |
| Amortization of operating lease right-of-use assets | 47,040 | 49,741 | 60,774 | 122,180 |
| Amortization of debt discount | - | 902,212 | 1,054,935 | - |
| Loss on disposal of fixed assets | - | - | -330 | - |
| Gain on change in fair value of warrant liability | - | - | - | -42,726 |
| Gain on change in derivative liability | - | -594,395 | 723,124 | - |
| (gain) / loss on disposal of fixed assets | - | 1,499 | - | 330 |
| Amortization of debt discount | 124,829 | - | - | 325,305 |
| Stock-based compensation | 224,981 | -132,875 | 609,167 | 1,263,419 |
| Loss on extinguishment of debt | -1,011,334 | - | - | - |
| Gain on change in derivative liability | -320,039 | - | - | 418,681 |
| Gain on change in fair value of warrant liability | 13,416 | 91,792 | -14,884 | - |
| Prepaid expenses | 436,458 | -26,390 | -14,398 | 135,808 |
| Accounts receivable | -65,566 | 8,723 | 119,488 | 79,023 |
| Other current assets | 98,785 | -171,106 | 20,269 | 101 |
| Deferred revenue, current and non-current | -713,041 | -88,461 | -405,072 | -107,559 |
| Accounts payable and accrued liabilities | 850,761 | -726,215 | 993,076 | -188,884 |
| Management and directors' fees payable | -12,156 | -34,883 | 61,430 | 24,306 |
| Right-of-use assets operating leases liabilities | -61,264 | -78,586 | -61,243 | -122,189 |
| Net cash used in operating activities | -5,280,132 | -5,491,867 | -3,630,760 | -10,560,707 |
| Purchases of property and equipment | 9,214 | 10,967 | 0 | 78,591 |
| Purchase of license | - | 0 | 0 | 0 |
| Net cash used in investing activities | -9,214 | -10,967 | 0 | -78,591 |
| Net proceeds from issuances of common shares | 5,173,805 | 6,715,777 | 2,007,419 | 2,447,214 |
| Tax withholdings paid related to stock-based compensation | 15,706 | 50,185 | 80,381 | 79,468 |
| Payments on convertible loan note | - | 833,334 | - | - |
| Proceeds from grants repayable | - | 78,617 | 32,426 | - |
| Net proceeds from issuances of convertible note and warrants | 1,755,000 | 28,577 | -28,597 | 5,802,799 |
| Payments on grants repayable | - | 0 | 32,426 | -32,426 |
| Proceeds from long-term debt | 962,723 | 410,002 | 0 | 1,570,176 |
| Payments on long-term debt | 246,186 | 180,376 | 285,350 | 411,824 |
| Payments on finance lease obligations | 13,460 | 13,273 | 13,142 | 24,219 |
| Net cash provided by financing activities | 7,616,176 | 6,155,805 | 1,599,949 | 9,337,104 |
| Effect of foreign exchange on cash | -341,041 | 264,650 | -25,778 | 293,761 |
| Net change in cash and cash equivalents | 1,985,789 | 917,621 | -2,056,589 | -1,008,433 |
| Cash and cash equivalents - beginning of the period | 1,117,028 | 199,407 | 3,264,429 | - |
| Cash and cash equivalents - end of the period | 3,102,817 | 1,117,028 | 199,407 | - |
VOLITIONRX LTD (VNRX)
VOLITIONRX LTD (VNRX)